Advertisement FDS Pharma acquires SciGen Israel hepatitis vaccine manufacturing plant - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDS Pharma acquires SciGen Israel hepatitis vaccine manufacturing plant

UK-based FDS Pharma has purchased the SciGen Israel's Rehovot hepatitis vaccine manufacturing plant for $2m in addition to 5% royalties on sales.

Run by Russian executives, FDS Pharma owns patents to vaccines and produces active pharmaceutical ingredients (APIs) for the Russian and other markets, according to globes.co.il.

Singapore-based SciGen, a subsidiary of Bioton is a fully integrated biotechnology company developing, manufacturing, and marketing biopharmaceuticals.

SciGen has set up the SciGen Israel plant for $10m, because of the financial difficulties, SciGen has divested SciGen Israel and its vaccine production and marketing rights.